Chris Hollowood, Freeline chairman (Syncona)
Freeline nabs $120M, eyes IPO as its gene therapy comes into focus
Freeline Therapeutics has landed another mega-round to back its gene therapy efforts and, on the same morning of the announcement, indicated that they could yet …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.